Anterior Uveitis-Pipeline Review, H2 2016

Anterior Uveitis-Pipeline Review, H2 2016

  • Products Id :- GMDHC8430IDB
  • |
  • Pages: 55
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Anterior Uveitis-Pipeline Review, H2 2016


Global Markets Direct's, 'Anterior Uveitis-Pipeline Review, H2 2016', provides an overview of the Anterior Uveitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Anterior Uveitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Anterior Uveitis and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.


The report provides a snapshot of the global therapeutic landscape of Anterior Uveitis

The report reviews pipeline therapeutics for Anterior Uveitis by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Anterior Uveitis therapeutics and enlists all their major and minor projects

The report assesses Anterior Uveitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Anterior Uveitis

Reasons to Buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Anterior Uveitis

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Anterior Uveitis pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Anterior Uveitis Overview 6

Therapeutics Development 7

Pipeline Products for Anterior Uveitis-Overview 7

Anterior Uveitis-Therapeutics under Development by Companies 8

Anterior Uveitis-Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Anterior Uveitis-Products under Development by Companies 12

Anterior Uveitis-Companies Involved in Therapeutics Development 13

Aciont Inc. 13

Aldeyra Therapeutics, Inc. 14

EyeGate Pharmaceuticals, Inc. 15

KPI Therapeutics, Inc. 16

Neuroptis Biotech 17

Anterior Uveitis-Therapeutics Assessment 18

Assessment by Monotherapy Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

dalazatide-Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

dexamethasone acetate-Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

dexamethasone sodium phosphate-Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

LME-636-Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

NOP-3-Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

NS-2-Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

Anterior Uveitis-Dormant Projects 44

Anterior Uveitis-Discontinued Products 45

Anterior Uveitis-Product Development Milestones 46

Featured News & Press Releases 46

May 09, 2016: Aldeyra Therapeutics Announces Positive Results From Phase II Clinical Trial in Subjects With Noninfectious Anterior Uveitis 46

Mar 02, 2016: EyeGate Receives Additional Milestone Payment From Valeant Pharmaceuticals for EGP-437 47

Jan 19, 2016: EyeGate Pharma Enrolls First Patient in Confirmatory Phase 3 Clinical Trial EGP-437-006 for Non-Infectious Anterior Uveitis 47

May 04, 2015: EyeGate Pharma Receives Positive Guidance From FDA on NDA Filing Requirements of EGP-437 for the Treatment of Anterior Uveitis 48

Apr 16, 2015: Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase II Clinical Trial 49

Mar 26, 2015: Aldeyra Therapeutics Opens Enrollment in Noninfectious Anterior Uveitis Phase II Clinical Trial 49

Mar 19, 2015: Kineta's ShK-186 Shows Encouraging Early Results as Potential Therapy for Autoimmune Eye Diseases 49

Mar 02, 2015: Aldeyra Therapeutics Provides Update on NS2 Clinical Program 50

Feb 17, 2015: Kineta to Present New, Positive Data for ShK-186 in Autoimmune Eye Diseases and in ANCA Vasculitis at Upcoming Prestigious Science Conferences 50

Dec 18, 2014: Aldeyra Therapeutics Submits FDA IND Filing for Noninfectious Anterior Uveitis 51

Apr 09, 2013: EyeGate Pharma's EGP-437 Matches Standard-of-care's Response Rate In Phase III Study In Patients With Anterior Uveitis 51

Dec 18, 2012: EyeGate Pharma Enrolls Last Patient In Pivotal Phase III Anterior Uveitis Study Of EGP-437 52

Jan 05, 2012: EyeGate Pharma Initiates Phase III Study Of EGP-437 In Patients With Anterior Uveitis 53

Appendix 54

Methodology 54

Coverage 54

Secondary Research 54

Primary Research 54

Expert Panel Validation 54

Contact Us 54

Disclaimer 55

List of Figures

Number of Products under Development for Anterior Uveitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Targets, H2 2016 19

Number of Products by Stage and Targets, H2 2016 19

Number of Products by Mechanism of Actions, H2 2016 21

Number of Products by Stage and Mechanism of Actions, H2 2016 21

Number of Products by Routes of Administration, H2 2016 23

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Molecule Types, H2 2016 25

Number of Products by Stage and Molecule Types, H2 2016 25

List of Tables

Number of Products under Development for Anterior Uveitis, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Anterior Uveitis-Pipeline by Aciont Inc., H2 2016 13

Anterior Uveitis-Pipeline by Aldeyra Therapeutics, Inc., H2 2016 14

Anterior Uveitis-Pipeline by EyeGate Pharmaceuticals, Inc., H2 2016 15

Anterior Uveitis-Pipeline by KPI Therapeutics, Inc., H2 2016 16

Anterior Uveitis-Pipeline by Neuroptis Biotech, H2 2016 17

Assessment by Monotherapy Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 24

Number of Products by Stage and Molecule Type, H2 2016 26

Anterior Uveitis-Dormant Projects, H2 2016 44

Anterior Uveitis-Discontinued Products, H2 2016 45

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Aciont Inc.

Aldeyra Therapeutics, Inc.

EyeGate Pharmaceuticals, Inc.

KPI Therapeutics, Inc.

Neuroptis Biotech

Anterior Uveitis Therapeutic Products under Development, Key Players in Anterior Uveitis Therapeutics, Anterior Uveitis Pipeline Overview, Anterior Uveitis Pipeline, Anterior Uveitis Pipeline Assessment

select a license

Single User License
USD 2000 INR 134900
Site License
USD 4000 INR 269800
Corporate User License
USD 6000 INR 404700



An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]